N. Pavlidis, The diagnostic and therapeutic management of leptomeningeal carcinomatosis, Ann Oncol, vol.15, pp.285-91, 2004.

J. L. Clarke, H. R. Perez, L. M. Jacks, K. S. Panageas, and L. M. Deangelis, Leptomeningeal metastases in the MRI era, Neurology, vol.74, pp.1449-54, 2010.

P. Beauchesne, Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours, Lancet Oncol, vol.11, issue.10, pp.70034-70040, 2010.

E. Le-rhun, S. Taillibert, and M. C. Chamberlain, Carcinomatous meningitis: Leptomeningeal metastases in solid tumors, Surg Neurol Int, vol.4, pp.265-88, 2013.

J. Hyun, I. H. Jeong, A. Joung, H. J. Cho, S. Kim et al., Leptomeningeal metastasis: clinical experience of 519 cases, Eur J Cancer, vol.56, pp.107-121, 2016.

B. Liao, J. Lee, C. Lin, Y. Chen, C. Chang et al., Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis, J Thorac Oncol, vol.10, pp.1754-61, 2015.

S. Umemura, K. Tsubouchi, H. Yoshioka, K. Hotta, N. Takigawa et al., Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: okayama lung cancer study group, Lung Cancer, vol.77, pp.134-143, 2012.

J. W. Riess, S. Nagpal, M. Iv, M. Zeineh, M. A. Gubens et al., Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era, Clin Lung Cancer, vol.15, pp.202-208, 2014.

F. Mack, B. G. Baumert, N. Schäfer, E. Hattingen, B. Scheffler et al., Therapy of leptomeningeal metastasis in solid tumors, Cancer Treat Rev, vol.43, pp.83-91, 2016.

M. Chamberlain, R. Soffietti, J. Raizer, R. Rud, D. Brandsma et al., Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials, Neuro-Oncology, vol.16, pp.1176-85, 2014.

M. C. Chamberlain, Leptomeningeal metastasis, Curr Opin Oncol, vol.22, pp.627-662, 2010.

S. K. Singh, J. M. Agris, N. E. Leeds, and L. E. Ginsberg, Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging, Radiology, vol.217, pp.50-53, 2000.

, Central Nervous System Cancers

C. Ma, Y. Lv, R. Jiang, J. Li, B. Wang et al., Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer, Oncol Lett, vol.11, pp.619-642, 2016.

L. Nayak, M. Fleisher, R. Gonzalez-espinoza, O. Lin, K. Panageas et al., Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors, Neurology, vol.80, pp.1598-605, 2013.

M. Shingyoji, H. Kageyama, T. Sakaida, T. Nakajima, Y. Matsui et al., Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis, J Thorac Oncol, vol.6, pp.1215-1235, 2011.

S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba et al., Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure, Respir Investig, vol.54, pp.14-23, 2016.

R. N. Hitchins, D. R. Bell, R. L. Woods, and J. A. Levi, A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis, J Clin Oncol, vol.5, pp.1655-62, 1987.

S. A. Grossman, D. M. Finkelstein, J. C. Ruckdeschel, D. L. Trump, T. Moynihan et al., Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group, J Clin Oncol, vol.11, pp.561-570, 1993.

M. J. Glantz, S. Lafollette, K. A. Jaeckle, W. Shapiro, L. Swinnen et al., Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis, J Clin Oncol, vol.17, pp.3110-3116, 1999.

M. J. Glantz, K. A. Jaeckle, M. C. Chamberlain, S. Phuphanich, L. Recht et al., A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors, Clin Cancer Res, vol.5, pp.3394-402, 1999.

W. Boogerd, M. J. Van-den-bent, P. J. Koehler, J. J. Heimans, J. J. Van-der-sande et al., The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study, Eur J Cancer, vol.40, pp.2726-2759, 2004.

M. J. Glantz, A. Van-horn, R. Fisher, and M. C. Chamberlain, Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis, Cancer, vol.116, pp.1947-52, 2010.

P. G. Morris, A. S. Reiner, O. R. Szenberg, J. L. Clarke, K. S. Panageas et al., Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy, J Thorac Oncol, vol.7, pp.382-387, 2012.

J. H. Park, Y. J. Kim, J. Lee, K. Lee, J. H. Kim et al., Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, Lung Cancer, vol.76, pp.387-92, 2012.

Y. Wu, L. Zhou, and Y. Lu, Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis, Oncol Lett, vol.12, pp.1301-1315, 2016.

M. Li, Q. Zhang, P. Fu, P. Li, A. Peng et al., Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials, PLoS ONE, vol.7, 2012.

S. L. Stapleton, J. M. Reid, P. A. Thompson, M. M. Ames, R. M. Mcgovern et al., Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates, Cancer Chemother Pharmacol, vol.59, pp.461-467, 2007.

F. Barlesi, R. Gervais, H. Lena, J. Hureaux, H. Berard et al., Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01), Ann Oncol, vol.22, pp.2466-70, 2011.

U. Herrlinger, H. Wiendl, M. Renninger, H. Förschler, J. Dichgans et al., Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value, Br J Cancer, vol.91, pp.219-243, 2004.

M. D. Groves, K. R. Hess, V. K. Puduvalli, H. Colman, C. A. Conrad et al., Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma, J Neurooncol, vol.94, pp.229-263, 2009.

A. Ilhan-mutlu, M. Osswald, Y. Liao, M. Gömmel, M. Reck et al., Bevacizumab prevents brain metastases formation in lung adenocarcinoma, Mol Cancer Ther, vol.15, pp.702-712, 2016.

P. Wu, C. Lin, C. Kuo, W. Chen, D. Yeh et al., A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis, BMC Cancer, vol.15, p.299, 2015.

C. Gani, A. C. Müller, F. Eckert, C. Schroeder, B. Bender et al., Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors, Strahlenther Onkol, vol.188, pp.148-53, 2012.

Z. Pan, G. Yang, H. He, G. Zhao, T. Yuan et al., Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study, Int J Cancer, vol.139, pp.1864-72, 2016.

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Biomarkers France contributors, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1441, 2016.

F. Barlesi, J. Mazieres, J. P. Merlio, D. Debieuvre, J. Masser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Intergroup (IFCT), The Lancet, 2016.

P. K. Paik, A. Drilon, P. Fan, H. Yu, N. Rekhtman et al., Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, vol.5, pp.842-851, 2015.

A. T. Shaw, S. Ou, Y. Bang, D. R. Camidge, B. J. Solomon et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, vol.371, pp.1963-71, 2014.

M. G. Kris, B. E. Johnson, L. D. Berry, D. J. Kwiatkowski, A. J. Iafrate et al., Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, vol.311, 1998.

Y. L. Wu, J. Yang, C. Zhou, J. Feng, S. Lu et al., BRAIN: a phase trial comparing WBI and chemotherapy with Icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201), J Clin Oncol, vol.34, 2016.

N. Reguart and J. Remon, Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosinekinase inhibitors, Future Oncol, vol.2015, pp.1-13

S. Matsumoto, K. Takahashi, R. Iwakawa, Y. Matsuno, Y. Nakanishi et al., Frequent EGFR mutations in brain metastases of lung adenocarcinoma, Int J Cancer, vol.119, pp.1491-1495, 2006.

T. Iuchi, M. Shingyoji, M. Itakura, S. Yokoi, Y. Moriya et al., Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations, Int J Clin Oncol, vol.20, pp.674-683, 2015.

Y. Li, B. Jiang, Y. Tu, H. Zhou, Q. Guo et al., Leptomeningeal metastases in patients with NSCLC with EGFR mutations, J Thorac Oncol, vol.11, pp.1962-1971, 2016.

J. L. Kuiper, L. E. Hendriks, A. J. Van-der-wekken, A. J. De-langen, I. Bahce et al., Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis, Lung Cancer, vol.89, pp.255-61, 2015.

Y. Lee, J. Han, H. T. Kim, T. Yun, G. K. Lee et al., Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung, J Neurooncol, vol.115, pp.95-101, 2013.

A. Omuro, M. G. Kris, V. A. Miller, E. Franceschi, N. Shah et al., High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib, Cancer, vol.103, pp.2344-2352, 2005.

Y. J. Lee, H. J. Choi, S. K. Kim, J. Chang, J. W. Moon et al., Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer, Cancer, vol.116, pp.1336-1379, 2010.

M. Jamal-hanjani and J. Spicer, Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer metastatic to the brain, Clin Cancer Res, vol.18, pp.938-982, 2012.

J. Zhao, M. Chen, W. Zhong, L. Zhang, L. Li et al., Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma, Clin Lung Cancer, vol.14, pp.188-93, 2013.

D. M. Jackman, A. J. Holmes, N. Lindeman, P. Y. Wen, S. Kesari et al., Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib, J Clin Oncol, vol.24, pp.4517-4537, 2006.

N. Dhruva and M. A. Socinski, Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib, J Clin Oncol, vol.27, pp.31-32, 2009.

T. Kawamura, A. Hata, J. Takeshita, S. Fujita, M. Hayashi et al., High-dose erlotinib for refractory leptomeningeal metastases after failure of standarddose EGFR-TKIs, Cancer Chemother Pharmacol, vol.75, pp.1261-1267, 2015.

J. L. Clarke, W. Pao, N. Wu, V. A. Miller, and A. B. Lassman, High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer, J Neurooncol, vol.99, pp.283-289, 2010.

D. M. Jackman, L. A. Cioffredi, L. Jacobs, F. Sharmeen, L. K. Morse et al., A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer, Oncotarget, vol.6, pp.4527-4563, 2015.

C. Grommes, G. R. Oxnard, M. G. Kris, V. A. Miller, W. Pao et al., Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer, Neuro-Oncology, vol.13, pp.1364-1373, 2011.

Y. Togashi, K. Masago, S. Masuda, T. Mizuno, M. Fukudo et al., Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer, Cancer Chemother Pharmacol, vol.70, pp.399-405, 2012.

E. Lee, B. Keam, D. Kim, T. M. Kim, S. Lee et al., Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.1069-74, 2013.

S. Tetsumoto, A. Osa, T. Kijima, T. Minami, H. Hirata et al., Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib, Int J Clin Oncol, vol.17, pp.155-164, 2012.

M. Schuler, Y. Wu, V. Hirsh, K. O'byrne, N. Yamamoto et al., First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases, J Thorac Oncol, vol.11, pp.380-90, 2016.

P. Hoffknecht, A. Tufman, T. Wehler, T. Pelzer, R. Wiewrodt et al., Afatinib Compassionate Use Consortium (ACUC), efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease, J Thorac Oncol, vol.10, pp.156-63, 2015.

A. Tamiya, M. Tamiya, T. Nishira, T. Shiroyama, K. Nakao et al., Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis, J Thorac Oncol, 2016.

L. V. Sequist, B. A. Waltman, D. Dias-santagata, S. Digumarthy, A. B. Turke et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, vol.3, 2011.

M. E. Arcila, G. R. Oxnard, K. Nafa, G. J. Riely, S. B. Solomon et al., Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay, Clin Cancer Res, vol.17, pp.1169-80, 2011.

H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, vol.19, pp.2240-2247, 2013.

D. Cross, S. E. Ashton, S. Ghiorghiu, C. Eberlein, C. A. Nebhan et al., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, vol.4, pp.1046-61, 2014.

P. Ballard, J. W. Yates, Z. Yang, D. Kim, J. Yang et al., Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 2016.

S. Nanjo, H. Ebi, S. Arai, S. Takeuchi, T. Yamada et al., High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells, Oncotarget, vol.7, pp.3847-56, 2016.

J. Yang, D. Kim, S. Kim, B. C. Cho, J. Lee et al., Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study, ASCO. Meeting Abstr, vol.34, p.9002, 2016.

A. Hata, N. Katakami, H. Yoshioka, R. Kaji, K. Masago et al., Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI, J Thorac Oncol, vol.10, pp.1553-1562, 2015.

T. Seto, T. Kato, M. Nishio, K. Goto, S. Atagi et al., Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, vol.15, pp.1236-1280, 2014.

R. Stahel, U. Dafni, O. Gautschi, E. Felip, A. Curioni-fontecedro et al., A phase II trial of erlotinib (E) and bevacizumab (B) _in patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutations with and without T790M mutation.Spanish Lung Cancer Group and the European Thoracic Oncology Platform BELIEF trial

E. Ichihara, K. Hotta, N. Nogami, S. Kuyama, D. Kishino et al., Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001, J Thorac Oncol, vol.10, pp.486-91, 2015.

L. Di, H. Rong, and B. Feng, Demystifying brain penetration in central nervous system drug discovery. Miniperspective, J Med Chem, vol.56, pp.2-12, 2013.

D. Kim, J. Yang, K. Chen, Z. Cheng, L. Yin et al., AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases, ASCO. Meeting Abstr, vol.33, p.8016, 2015.

M. Ahn, D. Kim, T. M. Kim, C. Lin, J. Ratnayake et al., Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-smallcell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM), ASCO Meeting Abstr, vol.34, p.9003, 2016.

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Biomarkers France contributors, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, 2016.

J. F. Gainor, S. Ou, J. Logan, L. F. Borges, and A. T. Shaw, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.1570-1573, 2013.

B. J. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.371, pp.2167-77, 2014.

A. T. Shaw, P. A. Janne, B. Besse, B. J. Solomon, F. H. Blackhall et al., Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007, ASCO Meeting Abst, vol.34, p.9066, 2016.

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crino et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-94, 2013.

A. T. Shaw, D. Kim, R. Mehra, D. Tan, E. Felip et al., Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, vol.370, pp.1189-97, 2014.

D. B. Costa, S. Kobayashi, S. S. Pandya, W. Yeo, Z. Shen et al., CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib, J Clin Oncol, vol.29, pp.443-448, 2011.

D. B. Costa, A. T. Shaw, S. Ou, B. J. Solomon, G. J. Riely et al., Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases, J Clin Oncol, vol.33, pp.1881-1889, 2015.

B. J. Solomon, F. Cappuzzo, E. Felip, F. H. Blackhall, D. B. Costa et al., Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 2016.

H. K. Ahn, B. Han, S. J. Lee, T. Lim, J. Sun et al., ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis, Lung Cancer, vol.76, pp.253-257, 2012.

D. Kim, R. Mehra, D. Tan, E. Felip, L. Chow et al., Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, vol.17, issue.15, pp.614-616, 2016.

L. Crinò, M. Ahn, D. Marinis, F. Groen, H. Wakelee et al., Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 2016.

S. M. Gadgeel, L. Gandhi, G. J. Riely, A. A. Chiappori, H. L. West et al., Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, vol.15, pp.70362-70368, 2014.

H. Nokihara, T. Hida, M. Kondo, Y. H. Kim, K. Azuma et al., Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study, ASCO. Meeting Abst, vol.34, p.9008, 2016.

J. F. Gainor, C. A. Sherman, K. Willoughby, J. Logan, E. Kennedy et al., Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib, J Thorac Oncol, vol.10, pp.232-238, 2015.

D. Kim, M. Tiseo, M. Ahn, K. L. Reckamp, H. Hansen et al., Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ nonsmall cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA), ASCO Meeting Abstr, vol.34, p.9007, 2016.

S. N. Gettinger, D. Kim, M. Tiseo, M. Langer, M. Ahn et al., Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials, J Clin Oncol, vol.34, 2016.

A. Abstr, , vol.06

T. W. Johnson, P. F. Richardson, S. Bailey, A. Brooun, B. J. Burke et al., ), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALKresistant mutations, J Med Chem, vol.15, pp.4720-4764, 2014.

H. Y. Zou, L. Friboulet, D. P. Kodack, L. D. Engstrom, Q. Li et al., PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models, Cancer Cell, vol.28, pp.70-81, 2015.

B. J. Solomon, T. M. Bauer, E. Felip, B. Besse, L. P. James et al., Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC), ASCO Meeting Abst, vol.34, p.9009, 2016.

J. Mazières, F. Barlesi, T. Filleron, B. Besse, I. Monnet et al., Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort, Ann Oncol, vol.27, pp.281-287, 2016.

F. Zagouri, T. N. Sergentanis, R. Bartsch, A. S. Berghoff, D. Chrysikos et al., Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis, Breast Cancer Res Treat, vol.139, pp.13-22, 2013.

B. C. Pestalozzi, S. Brignoli, . Trastuzumab-in, and . Csf, J Clin Oncol, vol.18, pp.2349-51, 2000.

H. Stemmler, M. Schmitt, A. Willems, H. Bernhard, N. Harbeck et al., Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs, vol.18, pp.23-31, 2007.

W. Park, H. Kim, K. Kim, S. Bae, N. Lee et al., Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis, Cancer Res Treat, vol.48, pp.843-850, 2016.

T. Nguyen-ngoc, H. Bouchaab, A. A. Adjei, and S. Peters, BRAF alterations as therapeutic targets in non-small-cell lung cancer, J Thorac Oncol, vol.10, pp.1396-403, 2015.

D. M. Hyman, I. Puzanov, V. Subbiah, J. E. Faris, I. Chau et al., Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N Engl J Med, vol.373, pp.726-762, 2015.

D. Planchard, B. Besse, H. Groen, P. Souquet, E. Quoix et al., Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol, vol.17, issue.16, pp.30146-30148, 2016.

C. S. Floudas, A. B. Chandra, and Y. Xu, Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival, Melanoma Res, vol.26, pp.312-317, 2016.

D. W. Kim, E. Barcena, U. N. Mehta, M. L. Rohlfs, A. J. Kumar et al., Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report, BMC Cancer, vol.15, p.400, 2015.

N. Schäfer, B. Scheffler, M. Stuplich, C. Schaub, S. Kebir et al., Vemurafenib for leptomeningeal melanomatosis, J Clin Oncol, vol.31, pp.173-174, 2013.

L. Sakji-dupré, L. Rhun, E. Templier, C. Desmedt, E. Blanchet et al., Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma, Melanoma Res, vol.25, pp.302-307, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-158, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, issue.15, pp.1281-1288, 2016.

F. Barlesi, P. Keunchil, F. Ciardiello, J. Von-pawel, S. Gadgeel et al., Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLC, ESMO, vol.2016

S. B. Goldberg, S. N. Gettinger, A. Mahajan, A. C. Chiang, R. S. Herbst et al., Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, openlabel, phase 2 trial, Lancet Oncol, vol.17, issue.16, pp.30053-30058, 2016.

E. Dudnik, S. Yust-katz, H. Nechushtan, D. A. Goldstein, A. Zer et al., Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases, Lung Cancer, vol.98, pp.114-121, 2016.

M. Chamberlain, L. Junck, D. Brandsma, R. Soffietti, R. Rudà et al., Leptomeningeal metastases: a RANO proposal for response criteria, Neuro-Oncology, 2016.